通过人工牛奶外体提供有针对性的C3G,用于有效治疗微塑料诱导的大肠炎
Yuanjie Wu1, Wen Chen2,1, Xiang Ye1,3
1ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou, 311215, China.
Materials today. Bio
|January 6, 2026
概括
使用外体体 (Exo-F6) 素-3-O-葡萄糖化物 (C3G) 的向输送有效治疗微塑料诱导的大肠炎. 这种新的方法通过调节微生物群和L-proline水平来增强C3G的生物可用性,减少炎症,并恢复肠道健康.
科学领域:
- 胃肠病学和肝病学
- 纳米医学是一种纳米医学.
- 食品科学与技术 食品科学与技术
背景情况:
- 摄入微塑料聚乙烯 (PS) 会导致慢性结肠炎,这是一个全球性的健康问题,治疗方法有限.
- 丁-3-O-葡萄糖化物 (C3G) 显示出抗结肠炎的潜力,但其结肠生物可用性较差.
- 外体因其生物相容性和可工程性而为向药物输送提供了一个有前途的平台.
研究的目的:
- 开发一种针对C3G的向输送系统,以提高其治疗大肠炎的疗效.
- 为了研究C3G载荷外体与抗MAdCAM-1抗体 (C3G@Exo-F6) 结合的治疗潜力,用于微塑料诱导的大肠炎.
主要方法:
- 对抗MAdCAM-1抗体 (F6) 与含有C3G (C3G@Exo-F6) 的原牛奶衍生外体的结合.
- 在体外评估C3G@Exo-F6稳定性和细胞吸收.
- 在 PS 诱导慢性结肠炎的小鼠模型中对 C3G@Exo-F6 的体内评估,包括 16S rRNA 测序和代谢学分析.
- 分子对接以阐明作用机制.
主要成果:
- C3G@Exo-F6在体外表现出增强的稳定性和细胞吸收.
- 在体内,C3G@Exo-F6显著抑制了炎症,恢复了肠道屏障的完整性,并在大肠炎小鼠中调节了肠道微生物群.
- C3G@Exo-F6增加了乳酸菌的丰度和L-proline水平,这与通过NR1D1.1.的TLR-4/COX-2炎症途径的抑制有关.
- 单独生奶外体 (Exo-F6) 也表现出抗炎作用.
结论:
- C3G@Exo-F6代表了一种强大的,来自食物的治疗策略,用于针对性治疗慢性结肠炎.
- 外体介导的向输送显著提高了C3G对微塑料诱导的结肠炎症的治疗疗效.
- 这种方法为解决与微塑料污染和炎症性肠道疾病有关的公共卫生问题提供了一个有希望的途径.
更多相关视频
相关概念视频
What is Monogastric Digestion?
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Gastritis III: Clinical Manifestations and Management
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Peptic Ulcer Disease IV: Management
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...


